At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 9 target
Drug / intervention
CAR-Tbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06136364Phase 1RecruitingUpdate OverdueUpdated 31mo ago · Completion was 22mo agoEnrollment Stalled
Update Overdue
Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL
In Brief
A Phase 1 clinical trial evaluating CAR-T for T-lymphoblastic Lymphoma and T-ALL. Currently recruiting, targeting 9 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsT-lymphoblastic Lymphoma, T-ALL
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
2024202520262027202820292030203120322033203420352036203720382039
Enrollment StartAug 2023
First PostedNov 2023
Primary CompletionAug 2024
TodayJul 2026
Study CompletionAug 2038
First PostedNov 18, 2023
Enrollment StartAug 15, 2023
Primary CompletionAug 15, 2024
Study CompletionAug 14, 2038
TodayJul 1, 2026
Enrollment to primary: 1 yearPosted 2.6 years ago
Interventions
CAR-Tbiological
CAR-T immunotherapy targeting CD7+